General Information
Product name
Atropine Sulfate Injection, USP
Manufacturer Name
Hospital Products Division
Emergency telephone
1-847-937-7970, 1-800-424-9300
Icons in SDS
Company Information
company name
Hospital Products Division
Section 2
Principle Routes of Exposure
Skin: Unlikely Inhalation: Unlikely Ingestion: Unlikely 3. HAZARDS INFORMATION, continued ----------------------- INGESTION RATING: Possibly toxic SKIN ABSORPTION RATING: N/D INHALATION RATING: N/D CORROSIVENESS RATING: N/D SKIN CONTACT RATING: N/D SKIN SENSITIZATION RATING: N/D EYE CONTACT RATING: N/D TARGET ORGANS: Parasympathetic nervous system, eyes, gastrointestinal tract, heart, central nervous system CARCINOGENICITY RATING NTP N/L IARC N/L OSHA N/L ACGIH: N/L None SIGNS AND SYMPTOMS: N/D. In clinical use, atropine can cause suppressed salivation, dilated pupils, blurred vision, hot/dry sensation, disorientation, increased heart rate, constipation, nausea, urinary retention and hesitancy, palpitation, dizziness, drowsiness, decreased bronchi secretion, photophobia, dry mouth, fever, glaucoma, difficulty breathing, flushing, rashes and vomiting. MEDICAL CONDITIONS AGGRAVATED BY EXPOSURE: N/D. Sensitivity to atropine and belladonna alkaloids. Concurrent glaucoma, tachycardia, gastrointestinal or biliary tract obstruction. Prostate hypertrophy.
